Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer cells
about
Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancerEmerging data on androgen receptor splice variants in prostate cancerThe role of epithelial plasticity in prostate cancer dissemination and treatment resistanceAndrogen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes.Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer.Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancerAre androgen receptor variants a substitute for the full-length receptor?Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide.Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.The presence of androgen receptor elements regulates ZEB1 expression in the absence of androgen receptor.A Whole Blood Assay for AR-V7 and ARv567es in Patients with Prostate Cancer.Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer.Dual effects of constitutively active androgen receptor and full-length androgen receptor for N-cadherin regulation in prostate cancer.DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7.[Androgen receptor variants in prostate cancer].Role of androgen receptor splice variants in prostate cancer metastasis.LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models.
P2860
Q26858922-726028A2-1E72-466A-88EB-FF0BBDE2C360Q28077830-37A96B67-2A68-4CD0-9427-E11B66EFA123Q34505037-213E294F-3247-4B7C-8D5A-EAE50D3073DFQ34734595-83A832C2-8F0E-49F2-9E6F-5D51E84D7CB7Q36563715-EAA9F09F-2422-4D8E-930E-5DEA900D34A9Q38276818-BE291215-0097-4008-8C30-231CDB607245Q38350089-84E97696-3773-433A-B5D6-E311AA70FD1BQ38541877-FE09F615-0ADA-41AF-945C-45E7CAD31AC6Q38835693-7485D29A-619C-48BE-AD60-87AEABFA50E8Q38962561-F5D19089-A342-4010-B6BA-D779D36CCC60Q39568878-56506B67-A73C-47A4-A7CD-C71BFFEA5A37Q41270542-B59E8510-4DD3-4A10-89DF-754A2E10626FQ42700843-42DCF228-0875-4428-8CA1-52A8FF10DE0EQ49712140-FF96CA35-9313-4CB0-BD5C-ED10C0BE57E5Q49845725-812A8BBA-766D-4647-A8F6-E4F88BC473B1Q53749556-D5492AAA-8361-4394-8C48-A92474E4088FQ55010012-EA455A01-292E-42CB-864B-8BA6FCD8B604
P2860
Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer cells
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Constitutively active androgen ...... rkers in prostate cancer cells
@ast
Constitutively active androgen ...... rkers in prostate cancer cells
@en
Constitutively active androgen ...... rkers in prostate cancer cells
@nl
type
label
Constitutively active androgen ...... rkers in prostate cancer cells
@ast
Constitutively active androgen ...... rkers in prostate cancer cells
@en
Constitutively active androgen ...... rkers in prostate cancer cells
@nl
prefLabel
Constitutively active androgen ...... rkers in prostate cancer cells
@ast
Constitutively active androgen ...... rkers in prostate cancer cells
@en
Constitutively active androgen ...... rkers in prostate cancer cells
@nl
P2093
P2860
P1433
P1476
Constitutively active androgen ...... rkers in prostate cancer cells
@en
P2093
Eva Erdmann
Félicie Cottard
Irène Asmane
Jean-Emmanuel Kurtz
Jean-Pierre Bergerat
P2860
P304
P356
10.1371/JOURNAL.PONE.0063466
P407
P577
2013-05-02T00:00:00Z